#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Dermatitis atopic Breast cancer metastatic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Cervix carcinoma recurrent Adenovirus infection Krabbe's disease Aspergillus infection Spinal cord injury Noonan syndrome Autoimmune myositis Neuroendocrine carcinoma of the skin Diffuse large B-cell lymphoma refractory Thalassaemia beta Thrombocytosis Cerebellar ataxia Chronic hepatitis B Anal cancer Hereditary hypophosphataemic rickets More trials…

    Learn about Rare Diseases

    Lysosomal storage disorder – Trials in Disease Alexander disease – Diagnostics Mantle cell lymphoma stage II – Life with Disease Mucopolysaccharidosis II – Basic Information Behcet’s syndrome – Diagnostics Loeys-Dietz syndrome Wiskott-Aldrich syndrome – Diagnostics Adrenogenital syndrome – Life with Disease Congenital generalised lipodystrophy – Basic Information Gaucher’s disease type III – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Salmeterol Masofaniten Fluoroestradiol F-18 Nido-361 Radium Ra 223 Dichloride Dipyridamole SEVUPARIN Tenofovir Disoproxil Digitoxin Encaleret Sulfate Acasunlimab Ertapenem Sodium Loperamide Hydrochloride Darunavir Raltegravir Sodium Bi 764524 Gallium (68Ga) Psma-R2 Gadoteridol Hst-1011 More therapies…

    Learn about Your Condition

    Pelvic venous thrombosis Bone marrow disorder Optic ischaemic neuropathy Congenital ureteric anomaly Acoustic neuroma Pancreatic carcinoma stage IV Albright's disease Chronic myeloid leukaemia Premature baby Chronic granulomatous disease Primary hyperaldosteronism Epithelioid sarcoma Solitary fibrous tumour Plasma cell myeloma refractory Portal hypertension More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Institut Paoli-Calmettes Cancer Centre

Institut Paoli-Calmettes Cancer Centre

2zy Baqpwlszw Dy Seiffs Mbzbcoksckr Bk 1wry Mymrguxadk 1qhxeu Fvgevs

Want to learn more about this study or check if you can participate? Contact us.

  • Study of Pivekimab Sunirine Combined with Venetoclax and Azacitidine in Adults with Newly Diagnosed Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy

    Recruiting

    4 1 1 1
    Investigated Diseases:
    • Acute myeloid leukaemia
    Investigated Drugs:
    • Pivekimab Sunirine
    • Azacitidine
    • Venetoclax
    Austria France Spain

  • Study of BGB-43395 with letrozole versus CDK4/6 inhibitor drug combination with letrozole in patients with untreated advanced HR‑positive HER2‑negative breast cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Abemaciclib
    • Palbociclib
    • Letrozole
    France Germany Italy Poland Spain

  • Study of precemtabart tocentecan alone or in drug combination versus standard therapy in previously treated metastatic colorectal cancer patients

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Bevacizumab
    • Tipiracil Hydrochloride
    • Trifluridine
    Austria Belgium Denmark France Germany Italy +3

  • Study of AZD0901 (sonesitatug vedotin) with capecitabine ± rilvegostomig in adults with advanced stomach or esophageal cancer (Claudin‑18.2‑positive, HER2‑negative)

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Oesophageal adenocarcinoma
    • Gastric cancer
    Investigated Drugs:
    • Azd0901
    • Zolbetuximab
    • Capecitabine
    Belgium France Germany Hungary Italy The Netherlands +2

  • Phase 3 study of ZL-1310 versus topotecan hydrochloride in patients with relapsed small cell lung cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Small cell lung cancer
    Investigated Drugs:
    • Topotecan Hydrochloride
    Austria Belgium Czechia Denmark France Germany +5

  • Durvalumab and Chemotherapy in Adults With Muscle-Invasive Bladder Cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Bladder cancer
    Investigated Drugs:
    • Durvalumab
    France Italy The Netherlands Spain

  • Long-Term Safety Study of Asciminib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Bosutinib
    • Dasatinib
    • Imatinib
    Austria Bulgaria Czechia Denmark France Germany +8

  • Obrixtamig, Carboplatin, and Etoposide for First-Line Treatment of Advanced Extrapulmonary Neuroendocrine Carcinoma in DLL3-Positive Patients

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Neuroendocrine carcinoma
    Investigated Drugs:
    • Igg-Like T Cell Engager Binding To Dll3 And Cd3
    • Carboplatin
    • Etoposide
    Austria Belgium Czechia Denmark Finland France +8

  • A Study of BI 764532, Atezolizumab, Carboplatin, and Etoposide in Patients With Extensive-Stage Small Cell Lung Cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Igg-Like T Cell Engager Binding To Dll3 And Cd3
    • Atezolizumab
    • Carboplatin
    Austria Belgium Bulgaria Czechia Estonia Finland +14

  • Comparing RO7771950 with a drug combination of tucatinib, trastuzumab, and capecitabine in patients with HER2-positive metastatic or locally advanced breast cancer

    Recruiting

    4 1 1 1
    Investigated Diseases:
    • HER2 positive breast cancer
    Investigated Drugs:
    • (R)-N-(4-([1,2,4]-TRIAZOLO[1,5-C]-PYRIMIDIN-7-YLOXY)-3-METHYLPHENYL)-5-((3,3-DIFLUORO-1-METHYLPIPERIDIN-4-YL)OXY)-6-METHOXYQUINAZOLIN-4-AMINE
    • Tucatinib
    • Capecitabine
    Austria Belgium Czechia France Germany Hungary +5
1 2 3 … 42
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!